Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 25, 2007

Glycominds and Fox Chase Cancer Center Partner to Discover Breast Cancer Diagnostic Blood Test

  • Glycominds entered into a research agreement with Fox Chase Cancer Center (FCCC) to develop a new blood test for breast cancer.

    “Glycominds’ antiglycan antibodies biomarkers approach together with FCCC’s excellent patient records, samples, and clinical know-how give this project a high basis for success,” asserts Nir Dotan, Ph.D., Glycominds’ cofounder, CTO, and vp of R&D.

    “I believe that glycan technology has the potential to enhance the early diagnosis of breast cancer,” notes Andrew K. Godwin, Ph.D., director of the clinical molecular genetics laboratory and the biosample repository at FCCC.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »